Quantum Biopharma Class B Subordinate Voting Shares
QNTM
6 hedge funds and large institutions have $12K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$8.28K |
| 2 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$4.31K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.64K |
| 4 |
SIM
Sonora Investment Management
Tucson,
Arizona
|
+$662 |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$662 |
Top Sellers
QNTM Hedge Fund Activity: Q1 2020 in Review
6 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q1 2020, worth a combined $12K.
Buyers outnumbered sellers: 6 funds opened new QNTM positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $8.28K.
- 6 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $12K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q1 2020.
- 6 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q1 2020 and 0 closed out, a net change of +6 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q1 2020 was Bank of Montreal, an estimated $8.28K added.
Based on aggregated 13F filings for Q1 2020.